Skip to main content

Gout

Serial plasma samples assayed for 92 inflammation-related proteins, during and after gout attacks. 21 were differentially expressed. Gout flares assoc w/ increased IL-6, CSF-1, VEGF-A & tumour necrosis factor superfamily 14 (TNFSF14 was highest) https://t.co/2p8vTFcmvD https://t.co/5z1gYdsKJO
Dr. John Cush @RheumNow( View Tweet )
Feb 25, 2024
UK Clinical Practice Research Datalink matched cohort study compared Gout (152K) to controls (709K) - CV devlopment higher in gout (21% vs 15%; HR 2.58). Moreso in women (HR 1.88). Gout pt had more CKD, HTN, obesity dyslipidaemia, & NIDDM https://t.co/BXCawnuIfa https://t.co/ZMuK9Msesb
Dr. John Cush @RheumNow( View Tweet )
Feb 22, 2024
Taiwan National Health claims data looked at drugs & gout flares. Signif increase flares were seen w/ ASA, thiazides, loop diuretics, ethambutol, pyrazinamide (1.15-3.35) & metformin (SR=1.14). Lower risk w/ fenofibrate (SR=0.60) & losartan (0.92) https://t.co/eBiiM83ei0 https://t.co/296XAbxwkc
Dr. John Cush @RheumNow( View Tweet )
Feb 17, 2024
Full read, review of COLCHICINE, a, w/ narrow therapeutic index, & assoc. w/ overdose & fatalities. Discuss Interactions, unauthorized access, overdoses, inappropriate dosing. No dose adjustments w/ Liver dz, but modest changes w/ severe CKD, dialysis https://t.co/53aOA4uqdY https://t.co/fuEwWsXMZG
Dr. John Cush @RheumNow( View Tweet )
Feb 11, 2024
Determinants of Gout Flares Approximately 12 million US adults in the US have gout. Two recent literature reports highlight contributors to gout flares. https://t.co/F2eiWXOTkF https://t.co/YFftaITmnQ
Dr. John Cush @RheumNow( View Tweet )
Feb 11, 2024

VITAL Info on Autoimmune Disease (2.9.2024)

Feb 09, 2024

Dr. Jack Cush reviews the journal reports from the past week on RheumNow.com. Highlights are summarized by three songs: "Stairway to Heaven", "You're No Good", and "How Long (has this been going on)".




  1. Many #RA pts remain on Steroids despite b/tsDMARD use! Study 228 #RA pts,

Read Article

Determinants of Gout Flares

Feb 06, 2024

Approximately 12 million US adults in the US have gout. Two recent literature reports highlight contributors to gout flares.



In JAMA, a retrospective review of 3613 gout patients with 3104 gout flares over 8.3 years showed an expected high rate of gout flares with higher baseline

Read Article
No evidence of harm starting urate lowering Tx (ULT) during #gout attack. Metanalysis 6 RCTs (445 pts) w/ gout attacks given ULT vs PBO or delayed ULT. No differences in pain, time to resolve gout flare or risk of recurrent gout flare in 30d (RR 1.06) https://t.co/Zk6OjJ8I2F https://t.co/prBQeSYH2Y
Dr. John Cush @RheumNow( View Tweet )
Feb 04, 2024
Remission in gout is 6 to 12 months with no flares. Lisa Stamp. #RNL2024 @RheumNow https://t.co/OlJK7HMNeX
Nouf Al hemmadi @NoufAhmedAlham2( View Tweet )
Jan 27, 2024
Role of anti- inflammatory prophylaxis when starting ULT in gout . 6 months. ? Longer period of prophylaxis or no prophylaxis? Lisa Stamp #RNL2024 @RheumNow https://t.co/sKKHWp9Ihw
Nouf Al hemmadi @NoufAhmedAlham2( View Tweet )
Jan 27, 2024
Serum urate level and gout flare. DECT images at baseline and target. Lisa Stamp. #RNL2024 @RheumNow https://t.co/z2PuoHnH2T
Nouf Al hemmadi @NoufAhmedAlham2( View Tweet )
Jan 27, 2024
@RheumNow #ACR2024 "Lest we forget the flare" - Lisa Stamp Studies are focused on uric acid levels, rather than flares - Less objective but more important to patients Consider initiation/discontinuation of prophylaxis with urate lowering T2T is only meaningful w ass. of flares

Eric Dein @ericdeinmd( View Tweet )

Jan 27, 2024
Dr Weber would add low dose #colchicine in pts who are at very high CV risk. Be careful with pts who have CKD #RNL2024 @rheumnow https://t.co/k00vqiQlI5
TheDaoIndex @KDAO2011( View Tweet )
Jan 27, 2024
No evidence of harm starting urate lowering Tx (ULT) during #gout attack. Metanalysis 6 RCTs (445 pts) w/ gout attacks given ULT vs PBO or delayed ULT. No differences in pain, time to resolve gout flare or risk of recurrent gout flare in 30d (RR 1.06) https://t.co/xUX2U6MmGP https://t.co/2bV0g2FOSK
Dr. John Cush @RheumNow( View Tweet )
Jan 24, 2024
Experience the Future of Rheumatology at RheumNow Live 2024, just two weeks away! Don't miss out – secure your spot today for an unforgettable journey into the latest advancements and insights. https://t.co/bbnb97MOHO https://t.co/QXO34ZmP2i
Dr. John Cush @RheumNow( View Tweet )
Jan 13, 2024

2023 Rheumatology Year in Review

Jan 12, 2024

Dr. Jack Cush reviews highlights, advances and hot topics in rheumatology from 2023 and the RheumNow website.  



2023 was a year of growth and new horizons while returning to operational and practice standards (in care and education) established before the pandemic.  



Below is

Read Article

New Year's Resolutions (1.5.2024)

Jan 05, 2024

Dr. Jack Cush imparts his new New Year's Resolutions for 2024 and also reviews the news and journal reports from the past week on RheumNow.com.

Read Article
Do I have Arthritis? How I handle this frequent curbside consult question... https://t.co/uX6MUfy59w https://t.co/kYviOhcLQj
Dr. John Cush @RheumNow( View Tweet )
Jan 04, 2024

Does Weight Loss Really Work in Gout?

Jan 03, 2024

A clinical trial has shown that obese gout patients will benefit from diet and lowered body weight, but weight loss was not associated with beneficial effects on serum urica acid (SUA), fatigue or pain.



Weight loss is commonly recommended as management strategy for gout patients. This

Read Article
Gout Flare Prophylaxis - Colchicine or NSAIDs? A new study suggests that colchicine, more so than non-steroidal anti-inflammatory drug (NSAID) prophylaxis, may increase the odds of adverse events, when initiating allopurinol for gout. https://t.co/mZZxTIUeQq https://t.co/43COjhNXUf
Dr. John Cush @RheumNow( View Tweet )
Dec 31, 2023
SGLT2 Inhibitors Reduce Gout Flares and CV Events. A cohort analysis shows that gout patients initiating sodium–glucose cotransporter-2 inhibitors (SGLT2is) had lower serum urate levels and fewer gouty flares requiring ED visits or hospitalizations. https://t.co/laOh4CsZ8Z https://t.co/6oas9AWc8j
Dr. John Cush @RheumNow( View Tweet )
Dec 30, 2023

Best of 2023: 2023 ACR/EULAR Criteria for Calcium Pyrophosphate Deposition Disease

Dec 22, 2023

The prevalence of radiographic chondrocalcinosis is estimated to be 4% to ≥10% in older adults, but the prevalence of symptomatic calcium pyrophosphate deposition (CPPD) disease is unknown. To advance our understanding of CPPD, the American College of Rheumatology and EULAR have published

Read Article

SGLT2 Inhibitors as Gout Treatment. Patients with gout and type 2 diabetes treated with SGLT2 inhibitors not only had reduced numbers of gout flares, but also lived longer compared with other such patients receiving other medications, researchers said. https://t.co/zJVJuvCoIm https://t.co/kDLJynYczc

Dr. John Cush @RheumNow( View Tweet )
Dec 21, 2023

DA Approves Canakinumab for Gout Flares The US FDA has approved canakinumab \ Ilaris\ for the treatment of gout flares in adults who cannot be treated with NSAIDs, colchicine, or repeated courses of corticosteroids. https://t.co/OX3wIajQtm https://t.co/tMDMc8ZKE8

Dr. John Cush @RheumNow( View Tweet )
Dec 20, 2023

Best of 2023: Colchicine or Prednisone in CPPD?

Dec 20, 2023

The COLCHICORT trial in patients with acute calcium pyrophosphate crystal arthritis (CPPD) demonstrated equivalent efficacy for both colchicine and prednisone, yet different safety signals were seen.

Read Article